Our data reinforces the idea of targeting EGFR activity as an interesting target to modulate MHC-II expression, either to potentiate it, as in the case of cancer, or to reduce it, as in the case of MS or other autoimmune diseases in which tolerance induction is one of the golden aims in cell therapy-based strategies [50]. The gene discussed is EGFR; the disease is myeloid sarcoma.